03:35 AM EDT, 04/04/2024 (MT Newswires) -- Standard BioTools ( LAB ) said late Wednesday it agreed to enter into a multi-year strategic engagement with Bristol-Myers Squibb ( BMY ) for the use of the SomaScan platform for translational medical research through 2026.

The financial terms of the agreement weren't disclosed.

The SomaScan platform is a proteomics technology that provides vast data and analysis of proteomic biomarkers. The platform is also being used to create a screening model for hypertrophic cardiomyopathy, according to Standard BioTools ( LAB ).

Price: 2.75, Change: +0.09, Percent Change: +3.38